KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced its recently expanded, state-of-the-art Geneva mammalian cell manufacturing facility has obtained a Swissmedic regulatory es...
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) tha...
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.
KBI Biopharma and Selexis, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.
Selexis SA announced today that Great Place to Work® has designated the Company among the “Best Workplaces Switzerland™” in 2022. This is the fifth straight year Selexis has earned this recognition.
KBI, a JSR Life Sciences company, held a ribbon-cutting at the company’s new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), No...